STOCK TITAN

[6-K] Haleon plc American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Haleon plc has filed a Form 6-K outlining the latest activity under the second tranche of its share-buyback programme announced on 31 July 2025.

On 6 Aug 2025 the company repurchased 1,517,728 ordinary shares on the London Stock Exchange at a volume-weighted average price of 347.5568 p (high 350.3000 p, low 346.3000 p). No shares were bought on Cboe BXE or CXE. All acquired shares will be cancelled.

Post-transaction, Haleon’s issued share capital totals 8,981,923,508 shares of £0.01 each, with 3,880,205 held in treasury, leaving 8,978,043,303 voting shares outstanding. The purchase equates to roughly 0.017 % of shares in issue and does not materially alter the company’s capital structure.

No earnings figures, guidance, or other material financial disclosures accompany this filing. The update is chiefly administrative, confirming incremental progress toward the ongoing buyback plan.

Haleon plc ha presentato un Modulo 6-K che illustra l'ultima attività relativa alla seconda tranche del suo programma di riacquisto di azioni annunciato il 31 luglio 2025.

Il 6 agosto 2025 la società ha riacquistato 1.517.728 azioni ordinarie alla Borsa di Londra a un prezzo medio ponderato per volume di 347,5568 p (massimo 350,3000 p, minimo 346,3000 p). Nessuna azione è stata acquistata su Cboe BXE o CXE. Tutte le azioni acquisite saranno annullate.

Dopo la transazione, il capitale sociale emesso di Haleon ammonta a 8.981.923.508 azioni del valore nominale di £0,01 ciascuna, con 3.880.205 azioni in portafoglio, lasciando 8.978.043.303 azioni con diritto di voto in circolazione. L'acquisto corrisponde a circa 0,017 % delle azioni emesse e non modifica in modo significativo la struttura del capitale della società.

Non sono stati forniti dati sugli utili, previsioni o altre informazioni finanziarie rilevanti con questa comunicazione. L'aggiornamento è principalmente di natura amministrativa, confermando il progresso incrementale del piano di riacquisto in corso.

Haleon plc ha presentado un Formulario 6-K que detalla la actividad más reciente bajo la segunda fase de su programa de recompra de acciones anunciado el 31 de julio de 2025.

El 6 de agosto de 2025, la compañía recompró 1.517.728 acciones ordinarias en la Bolsa de Londres a un precio medio ponderado por volumen de 347,5568 p (máximo 350,3000 p, mínimo 346,3000 p). No se adquirieron acciones en Cboe BXE o CXE. Todas las acciones adquiridas serán canceladas.

Tras la transacción, el capital social emitido de Haleon asciende a 8.981.923.508 acciones de £0,01 cada una, con 3.880.205 en tesorería, dejando 8.978.043.303 acciones con derecho a voto en circulación. La compra equivale a aproximadamente un 0,017 % de las acciones emitidas y no altera materialmente la estructura de capital de la empresa.

No se incluyen cifras de ganancias, previsiones ni otras divulgaciones financieras relevantes en esta presentación. La actualización es principalmente administrativa, confirmando el progreso incremental hacia el plan de recompra en curso.

Haleon plc는 2025년 7월 31일 발표한 주식 자사주 매입 프로그램 두 번째 분할에 따른 최신 활동을 담은 Form 6-K를 제출했습니다.

2025년 8월 6일, 회사는 런던 증권거래소에서 거래량 가중 평균 가격 347.5568 p(최고 350.3000 p, 최저 346.3000 p)로 1,517,728주의 보통주를 재매입했습니다. Cboe BXE나 CXE에서는 주식을 매입하지 않았으며, 취득한 모든 주식은 소각될 예정입니다.

거래 후 Haleon의 발행 주식 자본은 £0.01짜리 8,981,923,508주이며, 3,880,205주는 자사주로 보유 중이며, 의결권 있는 주식은 8,978,043,303주가 남아 있습니다. 이번 매입은 발행 주식의 약 0.017 %에 해당하며 회사의 자본 구조에 실질적인 변화를 주지 않습니다.

이번 제출에는 수익 수치, 가이드라인 또는 기타 중요한 재무 정보가 포함되어 있지 않습니다. 이 업데이트는 주로 행정적인 성격으로, 진행 중인 자사주 매입 계획의 점진적 진전을 확인하는 내용입니다.

Haleon plc a déposé un formulaire 6-K détaillant la dernière activité dans le cadre de la deuxième tranche de son programme de rachat d'actions annoncé le 31 juillet 2025.

Le 6 août 2025, la société a racheté 1 517 728 actions ordinaires à la Bourse de Londres à un prix moyen pondéré par volume de 347,5568 p (plus haut 350,3000 p, plus bas 346,3000 p). Aucune action n’a été achetée sur Cboe BXE ou CXE. Toutes les actions acquises seront annulées.

Après la transaction, le capital social émis de Haleon s’élève à 8 981 923 508 actions de £0,01 chacune, dont 3 880 205 en trésorerie, laissant 8 978 043 303 actions avec droit de vote en circulation. L’achat représente environ 0,017 % des actions en circulation et n’altère pas significativement la structure du capital de la société.

Aucun chiffre de résultat, prévision ou autre information financière importante n’accompagne ce dépôt. Cette mise à jour est principalement administrative, confirmant les progrès progressifs du plan de rachat en cours.

Haleon plc hat ein Formular 6-K eingereicht, das die neuesten Aktivitäten im Rahmen der zweiten Tranche ihres am 31. Juli 2025 angekündigten Aktienrückkaufprogramms darlegt.

Am 6. August 2025 hat das Unternehmen 1.517.728 Stammaktien an der Londoner Börse zu einem volumenbasierten Durchschnittspreis von 347,5568 p (hoch 350,3000 p, niedrig 346,3000 p) zurückgekauft. An den Börsen Cboe BXE oder CXE wurden keine Aktien erworben. Alle erworbenen Aktien werden annulliert.

Nach der Transaktion beläuft sich das ausgegebene Grundkapital von Haleon auf 8.981.923.508 Aktien mit einem Nennwert von je £0,01, davon werden 3.880.205 als eigene Aktien gehalten, sodass 8.978.043.303 stimmberechtigte Aktien im Umlauf sind. Der Rückkauf entspricht etwa 0,017 % der ausgegebenen Aktien und verändert die Kapitalstruktur des Unternehmens nicht wesentlich.

Mit dieser Einreichung werden keine Gewinnzahlen, Prognosen oder sonstige wesentliche finanzielle Angaben veröffentlicht. Das Update ist überwiegend administrativer Natur und bestätigt den fortschreitenden Fortschritt des laufenden Rückkaufprogramms.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small buyback (0.017% of shares) — positive signal but financially immaterial; neutral impact on valuation.

The 1.52 million-share repurchase demonstrates management’s commitment to capital return but represents a negligible fraction of the 8.98 billion shares outstanding. At ~347.6 p per share, the cash outlay is about £5.3 million, minor relative to Haleon’s market capitalisation. Because the shares are cancelled, future EPS is fractionally accretive, yet the impact is too small to shift consensus estimates or credit metrics. The filing contains no updates on operations, guidance, or liquidity, limiting its relevance to buy-side models. Overall, the action is directionally positive for shareholder returns but does not materially influence investment thesis or risk profile.

Haleon plc ha presentato un Modulo 6-K che illustra l'ultima attività relativa alla seconda tranche del suo programma di riacquisto di azioni annunciato il 31 luglio 2025.

Il 6 agosto 2025 la società ha riacquistato 1.517.728 azioni ordinarie alla Borsa di Londra a un prezzo medio ponderato per volume di 347,5568 p (massimo 350,3000 p, minimo 346,3000 p). Nessuna azione è stata acquistata su Cboe BXE o CXE. Tutte le azioni acquisite saranno annullate.

Dopo la transazione, il capitale sociale emesso di Haleon ammonta a 8.981.923.508 azioni del valore nominale di £0,01 ciascuna, con 3.880.205 azioni in portafoglio, lasciando 8.978.043.303 azioni con diritto di voto in circolazione. L'acquisto corrisponde a circa 0,017 % delle azioni emesse e non modifica in modo significativo la struttura del capitale della società.

Non sono stati forniti dati sugli utili, previsioni o altre informazioni finanziarie rilevanti con questa comunicazione. L'aggiornamento è principalmente di natura amministrativa, confermando il progresso incrementale del piano di riacquisto in corso.

Haleon plc ha presentado un Formulario 6-K que detalla la actividad más reciente bajo la segunda fase de su programa de recompra de acciones anunciado el 31 de julio de 2025.

El 6 de agosto de 2025, la compañía recompró 1.517.728 acciones ordinarias en la Bolsa de Londres a un precio medio ponderado por volumen de 347,5568 p (máximo 350,3000 p, mínimo 346,3000 p). No se adquirieron acciones en Cboe BXE o CXE. Todas las acciones adquiridas serán canceladas.

Tras la transacción, el capital social emitido de Haleon asciende a 8.981.923.508 acciones de £0,01 cada una, con 3.880.205 en tesorería, dejando 8.978.043.303 acciones con derecho a voto en circulación. La compra equivale a aproximadamente un 0,017 % de las acciones emitidas y no altera materialmente la estructura de capital de la empresa.

No se incluyen cifras de ganancias, previsiones ni otras divulgaciones financieras relevantes en esta presentación. La actualización es principalmente administrativa, confirmando el progreso incremental hacia el plan de recompra en curso.

Haleon plc는 2025년 7월 31일 발표한 주식 자사주 매입 프로그램 두 번째 분할에 따른 최신 활동을 담은 Form 6-K를 제출했습니다.

2025년 8월 6일, 회사는 런던 증권거래소에서 거래량 가중 평균 가격 347.5568 p(최고 350.3000 p, 최저 346.3000 p)로 1,517,728주의 보통주를 재매입했습니다. Cboe BXE나 CXE에서는 주식을 매입하지 않았으며, 취득한 모든 주식은 소각될 예정입니다.

거래 후 Haleon의 발행 주식 자본은 £0.01짜리 8,981,923,508주이며, 3,880,205주는 자사주로 보유 중이며, 의결권 있는 주식은 8,978,043,303주가 남아 있습니다. 이번 매입은 발행 주식의 약 0.017 %에 해당하며 회사의 자본 구조에 실질적인 변화를 주지 않습니다.

이번 제출에는 수익 수치, 가이드라인 또는 기타 중요한 재무 정보가 포함되어 있지 않습니다. 이 업데이트는 주로 행정적인 성격으로, 진행 중인 자사주 매입 계획의 점진적 진전을 확인하는 내용입니다.

Haleon plc a déposé un formulaire 6-K détaillant la dernière activité dans le cadre de la deuxième tranche de son programme de rachat d'actions annoncé le 31 juillet 2025.

Le 6 août 2025, la société a racheté 1 517 728 actions ordinaires à la Bourse de Londres à un prix moyen pondéré par volume de 347,5568 p (plus haut 350,3000 p, plus bas 346,3000 p). Aucune action n’a été achetée sur Cboe BXE ou CXE. Toutes les actions acquises seront annulées.

Après la transaction, le capital social émis de Haleon s’élève à 8 981 923 508 actions de £0,01 chacune, dont 3 880 205 en trésorerie, laissant 8 978 043 303 actions avec droit de vote en circulation. L’achat représente environ 0,017 % des actions en circulation et n’altère pas significativement la structure du capital de la société.

Aucun chiffre de résultat, prévision ou autre information financière importante n’accompagne ce dépôt. Cette mise à jour est principalement administrative, confirmant les progrès progressifs du plan de rachat en cours.

Haleon plc hat ein Formular 6-K eingereicht, das die neuesten Aktivitäten im Rahmen der zweiten Tranche ihres am 31. Juli 2025 angekündigten Aktienrückkaufprogramms darlegt.

Am 6. August 2025 hat das Unternehmen 1.517.728 Stammaktien an der Londoner Börse zu einem volumenbasierten Durchschnittspreis von 347,5568 p (hoch 350,3000 p, niedrig 346,3000 p) zurückgekauft. An den Börsen Cboe BXE oder CXE wurden keine Aktien erworben. Alle erworbenen Aktien werden annulliert.

Nach der Transaktion beläuft sich das ausgegebene Grundkapital von Haleon auf 8.981.923.508 Aktien mit einem Nennwert von je £0,01, davon werden 3.880.205 als eigene Aktien gehalten, sodass 8.978.043.303 stimmberechtigte Aktien im Umlauf sind. Der Rückkauf entspricht etwa 0,017 % der ausgegebenen Aktien und verändert die Kapitalstruktur des Unternehmens nicht wesentlich.

Mit dieser Einreichung werden keine Gewinnzahlen, Prognosen oder sonstige wesentliche finanzielle Angaben veröffentlicht. Das Update ist überwiegend administrativer Natur und bestätigt den fortschreitenden Fortschritt des laufenden Rückkaufprogramms.

UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of August 2025
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F
 
Form 40-F
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
07 August 2025 - “Transaction in Own Shares”
 
 
 
 
99.1
 
 
Haleon plc: Transaction in own shares
 
07 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,517,728 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.
 
 
London Stock Exchange
CBOE (UK)/BXE
CBOE (UK)/CXE
Date of purchase:
06 August 2025
06 August 2025
06 August 2025
Number of Shares purchased:
1,517,728
-
-
Highest price paid per Share (p):
350.3000
-
-
Lowest price paid per Share (p):
346.3000
-
-
Volume weighted average price paid per Share (p):
347.5568
-
-
 
Following the settlement of the above, the Company's registered share capital is 8,981,923,508 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,978,043,303 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
 
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
 
http://www.rns-pdf.londonstockexchange.com/rns/3105U_1-2025-8-6.pdf
 
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
 
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
 
Enquiries
 
 
Investors
Media
Jo Russell  
+44 7787 392441
Zoë Bird
+44 7736 746167
Rakesh Patel     
+44 7552 484646
Victoria Durman
+44 7894 505730
Email: investor-relations@haleon.com
Email: corporate.media@haleon.com
 
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
 
For more information, please visit www.haleon.com
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: August 07, 2025
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary

FAQ

How many Haleon (HLN) shares were repurchased in the August 2025 Form 6-K?

The company bought 1,517,728 ordinary shares on 6 August 2025.

What was the average price paid per repurchased Haleon share?

The volume-weighted average price was 347.5568 p per share.

What is Haleon’s updated number of voting shares after the buyback?

Voting shares outstanding now total 8,978,043,303.

Does the 6-K include any new earnings or guidance information for HLN?

No. The filing is limited to the share-buyback transaction and contains no earnings or guidance updates.

Where can investors find the detailed trade breakdown for Haleon’s buyback?

A full list of individual trades is available at http://www.rns-pdf.londonstockexchange.com/rns/3105U_1-2025-8-6.pdf.
Haleon

NYSE:HLN

HLN Rankings

HLN Latest News

HLN Latest SEC Filings

HLN Stock Data

41.53B
4.49B
0.02%
12.67%
0.49%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United Kingdom
Weybridge